Ventana Biotech Inc

Ventana Biotech Inc

August 27, 2009 09:57 ET

Ventana Enters Into a Multi Billion Dollar Market

NEW YORK, NEW YORK--(Marketwire - Aug. 27, 2009) - Ventana Biotech Inc. ("Ventana") (PINK SHEETS:VNTA), a biotechnology company developing an appetite-suppressing chewing gum, today revealed its progress in the groundbreaking research in tackling yet another of the modern lifestyle-induced illnesses: Stress!

Ventana is proud to announce that its research in developing a stress-suppressing chewing gum is progressing. Ventana has already had success with an appetite-suppressing chewing gum. Ventana is validating the effect of a number of common natural and safe elements that combined will lower a person's level of stress hormones, without otherwise common side effects such as drowsiness, moodiness, lack of natural emotions or the like. At this point Ventana is both examining ways of immediately regulating the level of stress hormone, as well as a long-term pre-emptive reduction in the level of stress hormone. These preliminary trials are very promising, and Ventana is aiming to reveal further positive results in greater detail in early 2010.

Stress, which can render people unable to work for months, or in the worst cases cause permanent and irreversible Post Traumatic Stress Syndrome (PTSS) costs our society trillions of dollars each year. As stress and PTSS also affects coworkers, families and friends around the person suffering from it, the cost of one individual being crippled with stress is multiplied many times over as the case of stress causes "ripples" throughout the social network surrounding that person. This in turn can lead to others in the social network to suffer from stress themselves, and so forth.

When successful trials for Ventana's Stress-Suppressing Chewing Gum have been concluded, the patent will be out-licensed to Big Pharma companies such as GlaxoSmithKline, Novo Nordisk, and AstraZeneca who will then pay milestone and licensing fees to Ventana Biotech for use of the patents. The preliminary estimate of the royalty cash-flow from a successful Stress Suppressing drug is at USD 1.6 - 1.9 billion.

About Ventana Biotech Inc

Ventana is positioning itself as the leading bioscience company in the development and commercial licensure of novel therapeutic anti-obesity drug treatment. The company leverages cutting-edge research collaborations to achieve breakthroughs in innovative anti-obesity treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

FORWARD-LOOKING STATEMENTS:

Statements about Ventana's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. Ventana's actual results could differ materially from expected results. Ventana does not undertake any obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this objective; Ventana will appropriately inform the public.

For more information about Ventana Biotech Inc please contact investor@ventanabiotech.com.

Contact Information

  • Ventana Biotech Inc.
    Janne Christensen, CEO
    BCB 1 Bachstrasse
    Butschwil CH-9606
    Switzerland
    Mobile: +44 7930 732 426